Dong-A ST announced on June 30 that it has signed a joint sales agreement with Ipsen Korea for "Diphereline," a treatment for precocious puberty and prostate cancer.
Diphereline is a GnRH (gonadotropin-releasing hormone) agonist developed by the global biopharmaceutical company Ipsen, used to treat central precocious puberty and prostate cancer.
Jaehoon Jung, President of Dong-A ST (right), and Miseon Yang, CEO of Ipsen Korea, are taking a commemorative photo at the signing ceremony of the joint sales agreement for Diphereline between Dong-A ST and Ipsen Korea. Photo by Dong-A ST
The signing ceremony was attended by Jaehoon Jung, President of Dong-A ST, Miseon Yang, CEO of Ipsen Korea, and other representatives from both companies, who pledged to strengthen their partnership.
Under the agreement, the two companies will jointly conduct domestic promotional and marketing activities for Diphereline starting July 1. Sales targeting general hospitals will be carried out in cooperation by both companies, while Dong-A ST will be solely responsible for sales targeting clinics and primary care institutions.
Dong-A ST has a portfolio that includes the growth hormone "Grotropin" and urology treatments "Zydena" and "Flivas," and possesses extensive sales and marketing experience and expertise accumulated in the fields of pediatric endocrinology and urology.
Ipsen Korea supplies a variety of oncology drugs in Korea, including "Diphereline," "Cabometyx" for advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer, and "Somatuline" for acromegaly and neuroendocrine tumors. Recently, the company has also entered the field of rare cholestatic liver diseases and plans to launch the new drug "Bilvay" for progressive familial intrahepatic cholestasis in Korea.
The two companies plan to actively expand Diphereline's presence in the domestic market by leveraging their accumulated capabilities and expertise to create synergy.
Miseon Yang, CEO of Ipsen Korea, stated, "Diphereline is a global standard medication for children suffering from precocious puberty and for prostate cancer patients who are concerned about the balance between masculinity and cancer treatment. Through Ipsen's scientific approach and Dong-A ST's expertise and network in the domestic market, we will be able to reach patients in Korea more closely."
Jaehoon Jung, President of Dong-A ST, said, "Our collaboration with Ipsen Korea will be a key opportunity to expand the domestic supply of Diphereline and improve patient access. By combining the strengths and expertise of both companies, we will provide more effective treatment options for patients in Korea and create synergy in the fields of precocious puberty and oncology."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
